![]() Neuron 101:133–151.e7ĭelfs JM, Zhu Y, Druhan JP et al (2000) Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Pharmacol Rev 48:355–402ĭe Jong JW, Afjei SA, Pollak Dorocic I et al (2019) A neural circuit mechanism for encoding aversive stimuli in the mesolimbic dopamine system. Alcohol Clin Exp Res 34:988–996Ĭolpaert FC (1996) System theory of pain and of opiate analgesia: no tolerance to opiates. J Abnorm Psychol 85:374–382Ĭhen AC, Manz N, Tang Y et al (2010) Single-nucleotide polymorphisms in corticotropin releasing hormone receptor 1 gene ( CRHR1) are associated with quantitative trait of event-related potential and alcohol dependence. ![]() Proc Natl Acad Sci U S A 112:15078–15083Ĭhapman LJ, Chapman JP, Raulin ML (1976) Scales for physical and social anhedonia. J Clin Invest 130:2480–2484Ĭase A, Deaton A (2015) Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Crit Rev Neurobiol 14:47–67Ĭarmack SA, Keeley RJ, Vendruscolo JCM et al (2019) Heroin addiction engages negative emotional learning brain circuits in rats. Neuropsychopharmacology 41:2147–2159Ĭarlezon WA Jr, Nestler EJ, Neve RL (2000) Herpes simplex virus-mediated gene transfer as a tool for neuropsychiatric research. Neuron 19:591–611īryce CA, Floresco SB (2016) Perturbations in effort-related decision-making driven by acute stress and corticotropin-releasing factor. J Neurosci 31:13246–13254īreiter HC, Gollub RL, Weisskoff RM et al (1997) Acute effects of cocaine on human brain activity and emotion. J Neurophysiol 73:568–585īogdan R, Santesso DL, Fagerness J et al (2011) Corticotropin-releasing hormone receptor type 1 (CRHR1) genetic variation and stress interact to influence reward learning. ![]() J Subst Abus Treat 56:48–53īester H, Menendez L, Besson JM et al (1995) Spino (trigemino) parabrachiohypothalamic pathway: electrophysiological evidence for an involvement in pain processes. Psychol Rev 111:33–51īentzley BS, Barth KS, Back SE et al (2015) Patient perspectives associated with intended duration of buprenorphine maintenance therapy. University of Nebraska Press, Lincoln, pp 257–323īaker TB, Piper ME, McCarthy DE et al (2004) Addiction motivation reformulated: an affective processing model of negative reinforcement. In: River PC (ed) Alcohol and addictive behavior, Nebraska symposium on motivation, vol vol 34. JAMA Psychiatry 74:511–519īaker TB, Morse E, Sherman JE (1987) The motivation to use drugs: a psychobiological analysis of urges. American Psychiatric Publishing, WashingtonĪshok AH, Mizuno Y, Volkow ND et al (2017) Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. Academic Press, San Diego, pp 495–578Īmerican Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. In: Paxinos G (ed) The rat nervous system, 2nd edn. Psychopharmacology 180:473–490Īlheid GF, De Olmos JS, Beltramino CA (1995) Amygdala and extended amygdala. KeywordsĪhmed SH, Koob GF (2005) The transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function. The overall hypothesis is that the shift in motivation toward negative reinforcement in addiction reflects the allostatic misregulation of hedonic tone, such that drug taking makes anhedonia worse during the process of seeking temporary relief by compulsive drug taking, thereby perpetuating the addiction cycle and hedonic comorbidities that are associated with addiction. The present review explores current knowledge of neurochemical neurocircuitry changes that are associated with conditioned hyperkatifeia/anhedonia. ![]() The neural substrates that mediate such anhedonia and crosstalk between elements of hyperkatifeia that contribute to anhedonia are then explored, including crosstalk between physical pain and emotional pain systems. The present review explores a heuristic framework for understanding the role of anhedonia in addiction, in which anhedonia is a key component of hyperkatifeia (conceptualized as the potentiated intensity of negative emotional/motivational symptoms during drug withdrawal) and negative reinforcement in addiction. ![]() Drug addiction has been defined as a chronically relapsing disorder that is characterized by a compulsion to seek and take a drug or stimulus, the loss of control in limiting intake, and the emergence of a negative emotional state when access to the drug or stimulus is prevented, a component of which is anhedonia. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |